Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Mouse (Murine) BCL6 Antibodies:
anti-Human BCL6 Antibodies:
anti-Rat (Rattus) BCL6 Antibodies:
Go to our pre-filtered search.
Human Monoclonal BCL6 Primary Antibody for IHC (p), ICS - ABIN967677
Baumjohann, Okada, Ansel: Cutting Edge: Distinct waves of BCL6 expression during T follicular helper cell development. in Journal of immunology (Baltimore, Md. : 1950) 2011
Show all 10 Pubmed References
Human Monoclonal BCL6 Primary Antibody for IHC, WB - ABIN2668887
García, García, Maestre, Lucas, Sánchez-Verde, Romero-Chala, Piris, Roncador: Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections. in The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2005
Show all 2 Pubmed References
Human Polyclonal BCL6 Primary Antibody for IF (p), IHC (p) - ABIN749843
Szabó, Gáspár, Dajnoki, Papp, Fábos, Szegedi, Zeher: Expansion of circulating follicular T helper cells associates with disease severity in childhood atopic dermatitis. in Immunology letters 2017
Human Polyclonal BCL6 Primary Antibody for WB - ABIN4283623
Margalit, Amram, Amariglio, Simon, Shaklai, Granot, Minsky, Shimoni, Harmelin, Givol, Shohat, Oren, Rechavi: BCL6 is regulated by p53 through a response element frequently disrupted in B-cell non-Hodgkin lymphoma. in Blood 2006
BCL6 forms a complex with BCL6 corepressor (BCoR (show BCOR Antibodies)) on the promoters of selected Notch (show NOTCH1 Antibodies) target genes such as enhancer of split related 1.
These findings indicate a role of the interaction between TH2-promoting factors and Bcl6 in promoting appropriate IL-4 (show IL4 Antibodies) production in mTH2 (show NUDT15 Antibodies) cells and suggest that chronic allergic diseases involve the TH2-promoting factor-mediated functional breakdown of Bcl6, resulting in allergy exacerbation.
Bioinformatics analysis and the dual-luciferase reporter assay demonstrated that miR (show MLXIP Antibodies)-10b could target the 3'-untranslated regions of B cell lymphoma 6 (Bcl6) which is an important regulator of osteoblast differentiation.
Def6 (show DEF6 Antibodies) limits proliferation of T follicular helper cells in mice via alteration of mTORC1 signaling and inhibition of Bcl6 expression.
The balance between CD4 (show CD4 Antibodies)(+) cytotoxic T cell and follicular helper T(Tfh) differentiation heavily depends on the class of infecting virus and is jointly regulated by the Tfh-related transcription factors Bcl6 and Tcf7 (show TCF7 Antibodies) (encoding TCF-1 (show HNF1A Antibodies)) and by the expression of the inhibitory receptors PD-1 (show PDCD1 Antibodies) and LAG3 (show LAG3 Antibodies).
Study provides evidence for an essential role of Bcl6 in the complex regulation of gene transcription during early adipogenesis. The action of Bcl6 is at least partially mediated by the direct transcriptional activation of STAT1 (show STAT1 Antibodies).
These data describe a novel regulatory mechanism through which STAT3 (show STAT3 Antibodies) and the Ikaros (show IKZF1 Antibodies) zinc finger transcription factors Aiolos (show IKZF3 Antibodies) and Ikaros (show IKZF1 Antibodies) cooperate to regulate Bcl-6 expression.
Our data reveal a regulatory role of BCL6 in inhibiting antiviral resistance factors in follicular Th cells
data provide a novel mechanism for positive control of gene expression by Bcl6, and illuminate how Bcl6 and Blimp1 (show PRDM1 Antibodies) control follicular helper T cell differentiation
both mouse and human B cells, IFN-gamma (show IFNG Antibodies) synergized with B cell receptor, toll (show TLR4 Antibodies)-like receptor, and/or CD40 (show CD40 Antibodies) activation signals to promote cell-intrinsic expression of the GC master transcription factor, B cell lymphoma 6 protein.
observations reveal that KLF6 (show KLF6 Antibodies) repress BCL6 to enhance macrophage inflammatory gene expression and function.
IFN gamma induced (show SAMHD1 Antibodies) upregulation of BCL6 was dependent on the classical STAT1 (show STAT1 Antibodies) signaling pathway, and affected both major BCL6 variants. Interestingly, although IFN alpha (show IFNA Antibodies) induced stronger STAT1 (show STAT1 Antibodies) phosphorylation than IFN gamma (show IFNG Antibodies), it only slightly upregulated BCL6 in multiple myeloma lines.
Findings demonstrate that BCL6 expression is downregulated by miR (show MLXIP Antibodies)-519d which targets its 3 '-UTR (show UTS2R Antibodies). Also, BCL6 mediates the repression of miR (show MLXIP Antibodies)-519d on cell proliferation and invasive capability of gastric cancer cells.
In Pakistani population, the frequency of GCB (show GBA Antibodies) type DLBCL [diffuse large B cell lymphoma ]expressing CD10 (show MME Antibodies) and BCL6 is 37.5%, and non- GCB (show GBA Antibodies) type DLBCL [diffuse large B cell lymphoma ] expressing MUM1 (show IRF4 Antibodies) is 62.5%.
BCOR (show BCOR Antibodies) internal tandem duplication and/or nuclear immunoreactivity for BCOR (show BCOR Antibodies) or BCL6 can aid in the diagnosis of primitive myxoid mesenchymal tumor of infancy and help to differentiate it from congenital infantile fibrosarcoma.
our findings provide a novel apoptotic regulatory pathway in which LITAF (show LITAF Antibodies), as a transcription factor, inhibits the expression of BCL6, which leads to activation of the intrinsic mitochondrial pathway and tumor apoptosis.
Ikaros (show IKZF1 Antibodies) regulates expression of the BCL6/BACH2 (show BACH2 Antibodies) axis in acute lymphoblastic leukemia cells.
our work casts new light on the biology of mantle cell lymphoma (MCL (show FH Antibodies)), revealing the role of SOX11 (show SOX11 Antibodies) exerting a functional effect through the repression of BCL6 transcription in MCL (show FH Antibodies) cells
BCL6 inhibitors have been shown to exert potent effects against these tumor types. Moreover, mechanism-based combinations of BCL6 inhibitors with other agents have yielded synergistic and often quite dramatic activity. Hence, there is a compelling case to accelerate the development of BCL6-targeted therapies for translation to the clinical setting
High BCL6 expression is associated with good response to chemotherapy in acute lymphoblastic leukemia.
this study show that PATZ1 (show ZNF278 Antibodies) expression correlates positively with BAX (show BAX Antibodies) and negatively with BCL6 and survival in human diffuse large B cell lymphomas
The protein encoded by this gene is a zinc finger transcription factor and contains an N-terminal POZ domain. This protein acts as a sequence-specific repressor of transcription, and has been shown to modulate the transcription of START-dependent IL-4 responses of B cells. This protein can interact with a variety of POZ-containing proteins that function as transcription corepressors. This gene is found to be frequently translocated and hypermutated in diffuse large-cell lymphoma (DLCL), and may be involved in the pathogenesis of DLCL. Alternatively spliced transcript variants encoding different protein isoforms have been found for this gene.
B-cell CLL/lymphoma 6
, B-cell CLL/lymphoma 6 (zinc finger protein 51)
, B-cell lymphoma 6 protein
, zinc finger protein 51
, B-cell leukemia/lymphoma 5
, B-cell leukemia/lymphoma 6
, B-cell lymphoma 6 protein homolog
, B-cell lymphoma 5 protein
, B-cell lymphoma 6 protein transcript
, cys-his2 zinc finger transcription factor
, lymphoma-associated zinc finger gene on chromosome 3
, protein LAZ-3
, zinc finger and BTB domain-containing protein 27
, zinc finger transcription factor BCL6S